Enanta Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 9.34

ENTA Stock  USD 9.34  0.03  0.32%   
Enanta Pharmaceuticals' future price is the expected price of Enanta Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Enanta Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Enanta Pharmaceuticals Backtesting, Enanta Pharmaceuticals Valuation, Enanta Pharmaceuticals Correlation, Enanta Pharmaceuticals Hype Analysis, Enanta Pharmaceuticals Volatility, Enanta Pharmaceuticals History as well as Enanta Pharmaceuticals Performance.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.
  
At present, Enanta Pharmaceuticals' Price Book Value Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 1.92, whereas Price To Sales Ratio is forecasted to decline to 2.53. Please specify Enanta Pharmaceuticals' target price for which you would like Enanta Pharmaceuticals odds to be computed.

Enanta Pharmaceuticals Target Price Odds to finish over 9.34

The tendency of Enanta Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 9.34 90 days 9.34 
about 98.0
Based on a normal probability distribution, the odds of Enanta Pharmaceuticals to move above the current price in 90 days from now is about 98.0 (This Enanta Pharmaceuticals probability density function shows the probability of Enanta Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Enanta Pharmaceuticals has a beta of 0.87 suggesting Enanta Pharmaceuticals market returns are sensitive to returns on the market. As the market goes up or down, Enanta Pharmaceuticals is expected to follow. Additionally Enanta Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Enanta Pharmaceuticals Price Density   
       Price  

Predictive Modules for Enanta Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Enanta Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Enanta Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
6.679.2011.73
Details
Intrinsic
Valuation
LowRealHigh
8.4114.1816.71
Details
Naive
Forecast
LowNextHigh
6.869.3911.92
Details
8 Analysts
Consensus
LowTargetHigh
25.3827.8930.96
Details

Enanta Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Enanta Pharmaceuticals is not an exception. The market had few large corrections towards the Enanta Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Enanta Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Enanta Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.53
β
Beta against Dow Jones0.87
σ
Overall volatility
1.02
Ir
Information ratio -0.21

Enanta Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Enanta Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Enanta Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Enanta Pharmaceuticals generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 79.2 M. Net Loss for the year was (133.82 M) with profit before overhead, payroll, taxes, and interest of 86.16 M.
Enanta Pharmaceuticals currently holds about 253.29 M in cash with (103.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Enanta Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 94.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Acquisition by Peterson Kristine of 10800 shares of Enanta Pharmaceuticals at 47.72 subject to Rule 16b-3

Enanta Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Enanta Stock often depends not only on the future outlook of the current and potential Enanta Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Enanta Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding21 M
Cash And Short Term Investments369.9 M

Enanta Pharmaceuticals Technical Analysis

Enanta Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Enanta Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Enanta Pharmaceuticals. In general, you should focus on analyzing Enanta Stock price patterns and their correlations with different microeconomic environments and drivers.

Enanta Pharmaceuticals Predictive Forecast Models

Enanta Pharmaceuticals' time-series forecasting models is one of many Enanta Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Enanta Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Enanta Pharmaceuticals

Checking the ongoing alerts about Enanta Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Enanta Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Enanta Pharmaceuticals generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 79.2 M. Net Loss for the year was (133.82 M) with profit before overhead, payroll, taxes, and interest of 86.16 M.
Enanta Pharmaceuticals currently holds about 253.29 M in cash with (103.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Enanta Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 94.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Acquisition by Peterson Kristine of 10800 shares of Enanta Pharmaceuticals at 47.72 subject to Rule 16b-3
When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.66)
Earnings Share
(5.45)
Revenue Per Share
3.407
Quarterly Revenue Growth
(0.05)
Return On Assets
(0.17)
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.